Gilead Sciences vs Amgen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Antiviral biopharma with $28.6B FY2024 revenue; Biktarvy $14B HIV franchise; lenacapavir 99%+ HIV prevention efficacy in 2024 trials is landmark breakthrough; Trodelvy oncology expansion.
About
Gilead Sciences is a biopharmaceutical company specializing in antiviral medicines, oncology, and inflammatory diseases, founded in 1987 and headquartered in Foster City, California, trading on Nasdaq (GILD). The company reported approximately $28.6 billion in total revenues for FY2024 under CEO Daniel O'Day, driven by the world's leading HIV treatment franchise anchored by Biktarvy—the world's best-selling antiretroviral therapy with over $14 billion in annual global sales—along with Veklury (remdesivir) for COVID-19 treatment, and a growing oncology portfolio including Trodelvy (sacituzumab govitecan, an ADC for breast and bladder cancer), Yescarta, and Tecartus (CAR-T cell therapies). Gilead's 2024 HIV prevention breakthrough—lenacapavir, a twice-yearly injection preventing HIV infection with near-100% efficacy in large clinical trials—represents potentially the most important HIV prevention advance since the development of daily oral PrEP.
Amgen (AMGN) reported $33.4B revenue in FY2024, up 19% YoY (post-Horizon acquisition). Top-5 global biotech. 10+ blockbuster drugs. ~24,000 employees. HQ: Thousand Oaks, CA. Market cap ~$130B.
About
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologics and brought landmark medicines including Epogen, Neupogen, and Enbrel to market. The company reported revenues of $33.4B in FY2024, up 19% year-over-year, boosted by the transformational $28B acquisition of Horizon Therapeutics in October 2023.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.